June #113 : How to Treat "Untreatable" HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Fighting Femmes

The amfAR's new clothes

Warm Reception

White Smoke In Our Eyes

Hepatitis on the Block

High On Adherence

A Positive Campaign

Founder's Letter

Earthwatch: Generic Meds

On The March!



POZ Picks Gay Pride

Medi - Mess

How to Treat "Untreatable" HIV

Read It Or Weep

Live and Let Die?

Did Common Just Come Out?

Legal Eye

Quick Study


Book nook


When Push Comes To Drag

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

June 2005

How to Treat "Untreatable" HIV

From last winter’s media frenzy, you’d think the New York City man infected with the highly resistant, very aggressive strain of HIV—dubbed the “supervirus”—had run out of treatment hopes before he’d begun. But a careful reading of his test results—especially his resistance profile—revealed to his savvy Aaron Diamond AIDS Research Center (ADARC) doctors that even a supervirus has weaknesses that current HIV meds can exploit.

CD4 Count: 39 
Below 200—an AIDS diagnosis. Given the short time he’s been infected, such quick progression requires immediate treatment.

Viral Load: 280,000
High—might need meds even if he had more CD4s.

Viral Fitness (Replication Capacity): 165%
Resistance usually makes HIV less fit. A replication capacity (RC) 65% greater than nonresistant, wild-type HIV bucks the trend. 

Resistance Profile—22 mutations:

Nukes: Broad resistance, but some sensitivity to a few.
The mutations cause much nuke resistance, but it’s not all or nothing. Docs chose Viread and Videx, to which he had some sensitivity.

Non-Nukes: No K103N mutation; resistant to Viramune and Rescriptor; partially sensitive to Sustiva.
The lack of K103N, which causes cross-resistance to the entire class, is a break. The docs chose Sustiva.

Protease Inhibitors (PIs): Resistance to all.
The many PI mutations suggest that the entire powerful class is lost to him, because PI cross-resistance is so common. But as Cal Cohen, MD, of the Community Research Initiative of New England, says, both tipranavir and TMC 114, experimental PIs with unique resistance profiles, may serve should this combo tank.

Entry Inhibitors (EIs): No resistance.
The sole approved EI, Fuzeon, isn’t widely used, so it’s no surprise that he has no resistance. The docs fingered Fuzeon as the combo cornerstone. It seems potent against resistant HIV when teamed with another active drug—in this case, Sustiva.

Prognosis: After two months, the nukes-plus-Sustiva-and-Fuzeon combo was showing considerable, if incomplete, control of the virus. While the man remains seriously ill, he has grounds for hope. POZ wishes him success and hopes he has found the support and empowerment available in the AIDS community—far from the doom-and-gloom headlines and hype. 

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.